Healthcare Providers and Services
Company Overview of AlloSource, Inc.
AlloSource, Inc. operates as a tissue bank that develops, processes, and distributes standard and customized precision allograft products to the medical community in the United States and internationally. The company offers precise bone, skin, soft-tissue, and custom-machined allografts for use in an array of life-saving and life-enhancing medical procedures. It provides osteobiologic grafts, including AlloStem, cellular bone allograft for general bone grafting applications; AlloFuse DBM that includes gel, paste, and putty bone graft substitutes; and AlloFlex, a cancellous bone allograft. The company also offers cancellous and structural general orthopedic grafts; spinal grafts, including ce...
6278 South Troy Circle
Centennial, CO 80111
Founded in 1994
Key Executives for AlloSource, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer and Vice President
Vice President of Operations
General Counsel and Vice President of Corporate Compliance
Chairman of Medical Advisory Board and Senior Medical Director
Compensation as of Fiscal Year 2016.
AlloSource, Inc. Key Developments
AlloSource Supports NASA and Jet Propulsion Laboratory on Microbial Study
Aug 25 16
AlloSource worked with NASA and the Jet Propulsion Laboratory (JPL) on microbial research that could help improve medical care for astronauts in space. AlloSource collaborated with NASA and JPL scientists on a study to characterize the effects of zero gravity on antibiotic resistant genes in microorganisms taken from the International Space Station (ISS). In this role, AlloSource assisted in describing antimicrobial capabilities of microbes isolated from the ISS. The study, titled Targeted Amplification of Antibiotic Resistant Genes Associated with the International Space Station Environment, investigates the impact of zero gravity on microbes by looking at the change in resistance over time compared to similar strains on earth. The ongoing project will help NASA and JPL scientists and medical staff to more efficiently prescribe antibiotics on the ISS. In addition to participating in the study, AlloSource continues to leverage technologies developed by NASA and JPL for assembly and launch operations of various Mars missions specifically, rapid molecular microbial burden measurement and genetic inventory cataloging to advance microbial research in tissue processing. AlloSource will use the research on microbiological testing methods to look for new ways to rapidly detect the presence of microorganisms to benefit allograft availability for patients.
AlloSource Announces Launch of AlloFuse Cortical Fibers and the AlloFuse Fiber Boat, its New Innovative Demineralized Cortical Fiber Allografts
Jun 13 16
AlloSource announced the launch of two new innovative demineralized cortical fiber allografts, AlloFuse Cortical Fibers and the AlloFuse Fiber Boat, for use in a variety of spine and orthopedic procedures. TheraCell developed and patented the demineralized bone fiber (DBF) technology used in these products and partnered with AlloSource to implement manufacturing and establish a distribution network for the tissue. AlloFuse Cortical Fibers and the AlloFuse Fiber Boat represent the latest additions to the AlloFuse line of osteobiologic bone grafts, originally launched in 2009. These new DBF allografts consist of 100% demineralized cortical bone and offer a less costly alternative to synthetic bone void fillers. The size and geometry of the fibers have been optimized to provide exceptional handling characteristics for bone fusion procedures, primarily in spine and orthopedics.
Allosource Distributes First Bioengineered Blood Vessels for Humacyte Phase III Clinical Trial
May 23 16
AlloSource announced the distribution of investigational bioengineered blood vessels for Humacyte's Phase III clinical trials. The first shipment of vessels will be used in the upcoming Phase III clinical trial, which will investigate the potential of Humacyte's blood vessels to improve vascular access for hemodialysis patients with end-stage renal disease. The clinical trial will compare the efficacy of Humacyte's vessels to the current standard of care, synthetic blood vessel replacement with Polytetrafluoroethylene (PTFE) grafts. AlloSource and Humacyte entered into a strategic partnership in 2013, with AlloSource serving as the sole manufacturing partner for Humacyte's blood vessels. The investigational bioengineered vessels are produced using donated human vascular cells that are decellularized to remove the donor identity from the newly created vessels. This process results in the production of investigational human vascular grafts with the potential for implantation into any patient at the time of medical need.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|